Webcast FibroScan® Included in Key International Guidelines 2023

FibroScan® Included in Key International Guidelines 2023

 · US/Eastern

About This Webcast

What is the role of noninvasive tests, including VCTE™, for earlier identification and risk stratification of at-risk patients? Learn form Dr. Mazen Noureddin and Dr. Naim Alkhouri who review and discuss the patient clinical care pathways recommended by the main Gastroenterology and Diabetology guidelines in 2023 (AASLD, EASL, AGA, and AACE) and how to optimize patient management as NASH-dedicated therapies are on the horizon.

Speakers

Mazen Noureddin, MD, MHSc

Mazen Noureddin, MD, MHSc

Houston Methodist Hospital, Houston Research Institute in Houston, TX

⦿ Dr. Noureddin was the founding director of the Fatty Liver Program at Cedars-Sinai Medical Center. He recently relocated to Texas to establish a state-of-the-art Houston Research Institute. Dr. Noureddin completed his internal medicine residency at the University of Southern California (USC) and completed a hepatology fellowship at the National Institutes of Health (NIH), and a gastroenterology fellowship at the University of California, San Diego. He joined the University of Southern California (USC) as an Assistant Professor of Clinical Medicine in 2013. He was then recruited to Cedars-Sinai Medical Center in 2015 to establish its new fatty liver program. ⦿ Dr. Noureddin is internationally known for his research in the area of NAFLD/NASH and NASH related cirrhosis. He is an expert in non-invasive testing and biomarkers of NASH and cirrhosis. He has given invited lectures on NAFLD/NASH at national and international society meetings and serves on several steering committees/advisory boards for industry. Dr. Noureddin has been published in many journals including: The Lancet, Science Trinational Medicine, Journal of Hepatology, Journal of Clinical Investigation, Gastroenterology, Hepatology, Clinical Gastroenterology and Hepatology, and others.

Naim Alkhouri, MD

Naim Alkhouri, MD

Arizona Liver Health (ALH) in Phoenix, AZ

DR. NAIM ALKHOURI, MD – BIO ⦿Naim Alkhouri, M.D., is the Chief Medical Officer (CMO), Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ. Prior to joining ALH, Dr. Alkhouri served as the director of the Metabolic Health Center at the Texas Liver Institute and Associate Professor of Medicine and Pediatrics at the University of Texas (UT) Health in San Antonio, TX. ⦿Dr. Alkhouri completed his Gastroenterology and Transplant Hepatology training at the Cleveland Clinic, where he was also appointed Assistant Professor of Medicine and Director of the Metabolic Liver Disease Clinic at the Cleveland Clinic Digestive Disease and Surgery Institute. ⦿Dr. Alkhouri is a key opinion leader in the field of NASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global NASH trials and a member of the AASLD NASH Special Interest Group (NASH SIG). ⦿Dr. Alkhouri has been published in over 200 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his workat both national and international medical conferences.